A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Trial Profile

A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs MA09 retinal pigment epithelial cell replacement therapy-Advanced Cell Technology (Primary)
  • Indications Stargardt disease
  • Focus Adverse reactions
  • Sponsors Ocata Therapeutics
  • Most Recent Events

    • 03 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 21 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov record.
    • 24 Jun 2015 According to Ocata Therapeutics media release, pooled data from this and other four trials (see profiles 700243638, 700243711, 700255314, 700256343) has been presented as a Late Breaking Abstract at the International Society for Stem Cell Research (ISSCR) 13th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top